News & Events

Nearly half of phase 3 cancer clinical trials carried out by the NCI-sponsored SWOG Cancer Research Network were associated with clinical care guidelines or new drug approvals, a study in JAMA Network Open shows.

Findings from a new NCI study of patients who received radioactive iodine (RAI) treatment for hyperthyroidism show an association between the dose of treatment and long-term risk of death from solid cancers, including breast cancer.

The 2019 Annual Report to the Nation on the Status of Cancer finds overall cancer death rates continue to decline and cancer incidence dropped in men and remained stable in women. A special section reports on recent cancer trends in younger adults.

An NCI-led study shows rates for aggressive subtypes of uterine cancer rose rapidly among women ages 30 to 79 from 2000–2015. The findings, published in the Journal of Clinical Oncology, also reveal racial disparities in incidence and survival rates.

A new study provides insight into how cancer immunotherapy works and suggests ways to enhance the treatment’s effectiveness. The NCI-led study, published in Science, examined the effect of high potassium levels on T cells.

The 2019 Szent-Györgyi Prize for Progress in Cancer Research will be awarded to NCI’s Steven A. Rosenberg, M.D., Ph.D., for his pioneering role in the development of immunotherapy.

A research team from NIH and Global Good has developed a computer algorithm that can analyze digital images of the cervix and identify precancerous changes that require medical attention. The AI approach could be valuable in low-resource settings.

The BRCA Exchange, a global resource that includes data on thousands of inherited variants in the BRCA1/BRCA2 genes, is available to the public through a website and new smartphone app.

In a new study, NIH investigators found that patients treated with chemotherapy for most solid tumors had an increased risk of tMDS/AML, a rare but often fatal blood cancer. The study, which used population-based data, was published in JAMA Oncology.

A clinical trial showed that ibrutinib plus rituximab is superior to standard treatment for patients age 70 and younger with untreated chronic lymphocytic leukemia (CLL). Findings were announced at the American Society of Hematology annual meeting.